Vivanza Biosciences Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 515837, "name": "Vivanza Biosci.", "stock_name": "Vivanza Biosci.", "full_name": "Vivanza Biosciences Ltd", "name_url": "stocks-analysis/vivanza-biosci", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "1.90", "chg": -0.1, "chgp": "-5.0%", "dir": -1, "prev_price": "2.00", "mcapval": "8.00 Cr", "mcap": "Micro Cap", "scripcode": 530057, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 67, "indexname": "India SENSEX", "isin": "INE984E01035", "curr_date": "May 08", "curr_time": "", "bse_nse_vol": "96.35 k", "exc_status": "Active", "traded_date": "May 08, 2026", "traded_date_str": "2026 05 08", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vivanza-biosci-515837-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Vivanza Biosciences Falls 5.00%: Valuation Shifts and Q4 Losses Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-falls-500-valuation-shifts-and-q4-losses-shape-the-week-3983601", "imagepath": "", "date": "2026-05-09 17:05:41", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 4:</strong> Week opens at Rs.2.00</p>\n <p><strong>May 6:</strong> Valuation shifts signal changing price attractiveness</p>\n <p><strong>May 8:</strong> Q4 FY26 results reveal sharp loss reversal despite revenue surge</p>\n <p><strong>May 8:</strong> Stock closes week at Rs.1.90 (-5.00%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2.00</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1.90</div><div class=\"stat-change neg..." }, { "title": "Are Vivanza Biosciences Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-vivanza-biosciences-ltd-latest-results-good-or-bad-3982328", "imagepath": "", "date": "2026-05-08 19:18:11", "description": "Vivanza Biosciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges despite remarkable year-on-year revenue growth. The company reported net sales of ₹6.36 crores, reflecting an extraordinary increase of 1,225.00% compared to the same quarter last year. However, this figure represents a substantial sequential decline of 85.94% from ₹45.25 crores in Q3 FY26, raising concerns about revenue volatility and sustainability.\n\nThe net profit for the quarter was a loss of ₹0.45 crores, marking a 325.00% decline from the previous quarter and a 55.00% decline year-on-year. This loss indicates that the company is currently loss-making on a trailing twelve-month basis, which has led to questions regarding its ability to achieve sustainable profitability.\n\nThe operating profit before depreciation, interest, tax, and other income (PBDIT) turned negative at -₹0.24 crores, resulting in a..." }, { "title": "Vivanza Biosciences Q4 FY26: Sharp Loss Reversal Raises Red Flags Despite Revenue Surge", "link": "https://www.marketsmojo.com/news/result-analysis/vivanza-biosciences-q4-fy26-sharp-loss-reversal-raises-red-flags-despite-revenue-surge-3981988", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_quaterlyResult_3981988.png", "date": "2026-05-08 14:46:41", "description": "Vivanza Biosciences Ltd., the Gujarat-based pharmaceutical company with a market capitalisation of ₹8.00 crores, reported a troubling quarter-on-quarter deterioration in Q4 FY26, swinging to a net loss of ₹0.45 crores from a profit of ₹0.20 crores in the previous quarter. The 325.00% decline in profitability overshadowed an otherwise impressive year-on-year revenue growth trajectory, raising serious concerns about operational efficiency and cost management at the micro-cap pharmaceutical player." }, { "title": "Vivanza Biosciences Ltd: Valuation Shifts Signal Changing Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-changing-price-attractiveness-3976696", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_valuationdot_3976696.png", "date": "2026-05-06 08:00:25", "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in price attractiveness despite ongoing operational challenges and a tough market backdrop." }, { "title": "When is the next results date for Vivanza Biosciences Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-vivanza-biosciences-ltd-3976541", "imagepath": "", "date": "2026-05-05 23:16:40", "description": "The next results date for Vivanza Biosciences Ltd is scheduled for 07 May 2026...." }, { "title": "Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3969338", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VivanzaBioscien_valuationdot_3969338.png", "date": "2026-04-30 08:00:22", "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite ongoing challenges reflected in its negative returns and profitability metrics, the stock’s current price-to-earnings and price-to-book value ratios suggest a more compelling entry point compared to peers and historical averages." }, { "title": "When is the next results date for Vivanza Biosciences Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-vivanza-biosciences-ltd-3969194", "imagepath": "", "date": "2026-04-29 23:16:25", "description": "The next results date for Vivanza Biosciences Ltd is scheduled for 04 May 2026...." }, { "title": "Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3956641", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VivanzaBioscien_valuationdot_3956641.png", "date": "2026-04-22 08:00:51", "description": "Vivanza Biosciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade, despite ongoing challenges in profitability and returns. This change, driven primarily by a sharp correction in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks." }, { "title": "Vivanza Biosciences Gains 14.84%: 2 Key Factors Driving the Weekly Surge", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-gains-1484-2-key-factors-driving-the-weekly-surge-3943078", "imagepath": "", "date": "2026-04-11 17:04:52", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>6 Apr:</strong> Week opens at ₹1.82</p>\n <p><strong>7 Apr:</strong> Valuation shifts highlight renewed price attractiveness</p>\n <p><strong>8 Apr:</strong> MarketsMOJO upgrades rating from Strong Sell to Sell</p>\n <p><strong>10 Apr:</strong> Week closes at ₹2.09, +14.84% weekly gain</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1.82</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.2.09</div><div class=\"stat-change positive\">..." } ], "total": 190, "sid": "515837", "stock_news_url": "https://www.marketsmojo.com/news/vivanza-biosciences-515837" }, "announcements": [ { "caption": "Results- Quarterly And Year To End Dated 31St March 2026", "datetime": "07-May-2026", "details": "Audited Standalone Financial Results for the Quarter and Year ended on 31st March 2026 Took note of resignation of Hemant A. Parikh as an MD and Chaitra Arora a CS Reconstitution of Committees of the Board", "source": "BSE" }, { "caption": "Non Applicability Of Related Party Transaction Under Regulation 23(9) Of SEBI (LODR) Regulations 2015 For The Quarter And Year Ended 31St March 2026", "datetime": "07-May-2026", "details": "This is to inform you that as per Regulation 15(2) of SEBI (LODR) Regulations 2015 Corporate Governance and the above mentioned provisions such as Regulation 23(9) of SEBI (LODR) Regulations 2015 shall not apply to listed entities having paid up equity share capital not exceeding Rupees 10 crores and net worth not exceeding Rupees 25 crores as on the last day of previous financial year. The paid-up equity share capital and net worth of the Company as on 31st March 2025 are Rs. 40000000 and Rs. 40203752.40 respectively", "source": "BSE" }, { "caption": "Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended On 31St March 2026", "datetime": "07-May-2026", "details": "Consideration of Audited Financial Results Standalone and Consolidated as per Indian Accounting Standards (Ind AS) along with the Audit Report of the Company for the Quarter and Year ended 31st March 2026 Took note of the Resignation of Mr. Hemant Amrish Parikh as a Non-Executive Director of the Company Took note of the Resignation of CS Chaitra Arora from the position of the CS and compliance officer Reconstitution of Committees of the Board with effect from 07th May 2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Vivanza Biosciences Ltd has announced <strong>1:10</strong> stock split, ex-date: 24 Mar 23", "dt": "2023-03-24", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

May 4: Week opens at Rs.2.00

May 6: Valuation shifts signal changing price attractiveness

May 8: Q4 FY26 results reveal sharp loss reversal despite revenue surge

May 8: Stock closes week at Rs.1.90 (-5.00%)

Read full news article

Are Vivanza Biosciences Ltd latest results good or bad?

2026-05-08 19:18:11

Vivanza Biosciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges despite remarkable year-on-year revenue growth. The company reported net sales of ₹6.36 crores, reflecting an extraordinary increase of 1,225.00% compared to the same quarter last year. However, this figure represents a substantial sequential decline of 85.94% from ₹45.25 crores in Q3 FY26, raising concerns about revenue volatility and sustainability. The net profit for the quarter was a loss of ₹0.45 crores, marking a 325.00% decline from the previous quarter and a 55.00% decline year-on-year. This loss indicates that the company is currently loss-making on a trailing twelve-month basis, which has led to questions regarding its ability to achieve sustainable profitability. The operating profit before depreciation, interest, tax, and other income (PBDIT) turned negative at -₹0.24 crores, resulting in a...

Read full news article

Vivanza Biosciences Q4 FY26: Sharp Loss Reversal Raises Red Flags Despite Revenue Surge

2026-05-08 14:46:41

Vivanza Biosciences Ltd., the Gujarat-based pharmaceutical company with a market capitalisation of ₹8.00 crores, reported a troubling quarter-on-quarter deterioration in Q4 FY26, swinging to a net loss of ₹0.45 crores from a profit of ₹0.20 crores in the previous quarter. The 325.00% decline in profitability overshadowed an otherwise impressive year-on-year revenue growth trajectory, raising serious concerns about operational efficiency and cost management at the micro-cap pharmaceutical player.

Read full news article

Vivanza Biosciences Ltd: Valuation Shifts Signal Changing Price Attractiveness

2026-05-06 08:00:25

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in price attractiveness despite ongoing operational challenges and a tough market backdrop.

Read full news article

When is the next results date for Vivanza Biosciences Ltd?

2026-05-05 23:16:40

The next results date for Vivanza Biosciences Ltd is scheduled for 07 May 2026....

Read full news article

Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-04-30 08:00:22

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite ongoing challenges reflected in its negative returns and profitability metrics, the stock’s current price-to-earnings and price-to-book value ratios suggest a more compelling entry point compared to peers and historical averages.

Read full news article

When is the next results date for Vivanza Biosciences Ltd?

2026-04-29 23:16:25

The next results date for Vivanza Biosciences Ltd is scheduled for 04 May 2026....

Read full news article

Vivanza Biosciences Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-04-22 08:00:51

Vivanza Biosciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade, despite ongoing challenges in profitability and returns. This change, driven primarily by a sharp correction in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks.